The New Health
Navigating Risk and Seizing Opportunity in the Biopharmaceutical Industry’s Changing Landscape
Quintiles examines the complex challenges and opportunities facing the biopharmaceutical industry and how companies must manage risk, demonstrate greater value and improve patient outcomes.
Few industry narratives are as prevalent today as the need for biopharmaceutical companies to re-engineer their R&D model. Amid declining productivity, increasing costs, decreasing pipelines, lower earnings and a host of other challenges, the call has gone out for urgent action to transform and re-energize the drug development process. The biopharmaceutical industry is indeed entering into a New Health landscape, and success will certainly be determined by how well biopharma navigates the new risks of this landscape, learns to interact with new stakeholders such as health technology assessment (HTA) groups, payers and patients and as a result embraces the need for convergent thinking from the commercial and clinical domains within the clinical development process.
